APA (7th ed.) Citation

Onda, Y., Kanda, J., Kaneko, H., Shimura, Y., Fuchida, S., Nakaya, A., . . . Yagi, H. (2022). Real-world effectiveness and safety analysis of carfilzomib–lenalidomide–dexamethasone and carfilzomib–dexamethasone in relapsed/refractory multiple myeloma: A multicenter retrospective analysis. Therapeutic advances in hematology, 13, 1. https://doi.org/10.1177/20406207221104584

Chicago Style (17th ed.) Citation

Onda, Yoshiyuki, et al. "Real-world Effectiveness and Safety Analysis of Carfilzomib–lenalidomide–dexamethasone and Carfilzomib–dexamethasone in Relapsed/refractory Multiple Myeloma: A Multicenter Retrospective Analysis." Therapeutic Advances in Hematology 13 (2022): 1. https://doi.org/10.1177/20406207221104584.

MLA (9th ed.) Citation

Onda, Yoshiyuki, et al. "Real-world Effectiveness and Safety Analysis of Carfilzomib–lenalidomide–dexamethasone and Carfilzomib–dexamethasone in Relapsed/refractory Multiple Myeloma: A Multicenter Retrospective Analysis." Therapeutic Advances in Hematology, vol. 13, 2022, p. 1, https://doi.org/10.1177/20406207221104584.